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1. Introduction
  Malaria and HIV/AIDS are two disease conditions that are 
of great public health concern in sub-Saharan Africa. The 
dual infection of HIV and malaria fuels the spread of both 
diseases in sub-Saharan Africa. Malaria is responsible for 
more than 1 million deaths worldwide every year with about 
90% occurring in sub-Saharan Africa[1,2]. Also an estimated 
28 million individuals are currently infected with HIV in 
sub-Saharan Africa with almost 3 million deaths annually[3]. 
Expectedly, the overlap in the distribution of these two 
disease conditions makes co-infection and interaction 
inevitable even as morbidity and mortality increases.
  In East and Southern Africa where HIV prevalence is near 
30%, it is estimated that by the end of 2009, an estimated 
3.3 million people would be living with HIV in Nigeria[4]. 
Nigeria is considered an area of stable Plasmodium 
falciparum transmission. Her adult prevalence of HIV has 
dropped from 5.8% in 2001 to 4.4% in 2005[5] and 21%-
28% of people living with HIV/AIDS are co-infected with 
malaria[6,7].
  Previous studies have shown evidence of detrimental 
relationship between the two disease conditions especially 
in areas where they are co-endemic[6-9]. On one hand, 
HIV infection has been reported to roughly double the risk 
of malaria parasitemia and increase the frequency and 
severity of clinical malaria[8,9]. On the other hand, clinical 
malaria has been reported to facilitate the HIV replication 
through incitement of cytokine production and immune-
cell activation[10-12]. The increased rate of HIV replication 
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leads to a lasting elevation in viral load, which in turn 
hasten immune system decline and HIV disease progression 
to AIDS and death or increase the risk of its transmission[13-
15].
  The potential risks of adverse drug interactions have critical 
implications for effective management of co-infection. Such 
interactions may result in treatment failures, especially 
with sulfa-based drugs, or toxicity. While antiretroviral 
protease inhibitors have demonstrated some antimalarial 
effects, co-trimoxazole prophylaxis have been reported 
to prevent malaria episodes in HIV-infected patients[16]. 
Therefore identification of the best methods for reducing the 
incidence of malaria in adults with HIV infection and better 
understanding of the relationship between HIV disease and 
malaria could improve clinical and public health strategies. 
The aim of this paper is to study the prevalence of malaria 
parasitemia, CD4+ cell count and some haematological 
indices among co-infected HIV/malaria individual on highly 
active antiretroviral therapy (HAART) in an endemic region 
for both disease. 
2. Materials and methods
2.1. Participants and study design
  The study group comprised 342 adult HIV subjects with 
HAART attending the consultant outpatient HIV/AIDS clinic 
in the University of Benin Teaching Hospital, Benin City, 
Nigeria between June to November 2011. The hospital has 
a 700 bed capacity and is a major referral and treatment 
centre for the South-South geopolitical zone of Nigeria 
where two major HIV/AIDS treatment units exist: the Federal 
Government Sponsored Project and President Emergency 
Plan for AIDS Relief, USA. 
  After informed consent was obtained, individuals attending 
the clinic had detailed clinical history and examination, 
and biodata documented. Each patient was assigned an 
HIV stage according to the proposed WHO hierarchical 
staging classification based on clinical and performance 
criteria. For the purpose of this study they were grouped into 
asymptomatic (stage 1 and 2) and symptomatic (stage 3 and 
4) staging system of HIV/AIDS for Africa[17].
2.2. Laboratory methods
  All participants had regular CD4+ cell count and complete 
blood count measurements as part of routine workup to 
assess the disease severity. The haematological counts 
were determined by automation and CD4+ cell counts 
were counted by flow cytometry. The HIV status of each 
participant was already determined by screening their 
plasma samples with two parallel rapid tests for detecting 
HIV 栺 and 栻 antibodies (Abbott determine 1 & 2 and 
Capillus HIV-1/HIV-2) following the manufacturers’ 
instructions. Samples concordantly positive or negative on 
both assays were not tested further. 
  Thick and thin peripheral blood smears for malaria 
parasites were prepared from capillary blood harvested 
through finger prick on each subject, stained with 3% 
Giemsa stain at pH 7.2 for 30 minutes and was examined 
under 伊100 oil-immersion fields. Initially, the thin blood 
film was screened by observation of 100 fields, each 
representing about 200 erythrocytes, and the result was 
then adjusted to 5 million erythrocytes per one microliter to 
obtain the parasite count. In case of negative thin film, the 
parasite: leukocyte ratio was measured on the observation of 
1 000 leukocytes in the thick blood film, and the total white 
blood cell count of each participant was used in calculating 
the parasite count. Non-falciparum plasmodium species 
were excluded. A slide was positive for malaria with any 
level of parasitemia and significant parasite count at cut-off 
of 1.25伊109 parasites/L[8]. Anemia was defined as Hb<10 g/dL 
and thrombocytopenia as platelet count less than 150伊109/
L. All the participants investigated were already on HAART 
therapy and appropriate antimalaria drug regimen was given 
when diagnosis of malaria parasitemia was made. None of 
the patient was on antimalaria prophylaxis. 
  The study was given ethical approval by the hospital. The 
first-line ART treatment regimen consisted of stavudine, 
lamivudine and either nevirapine or efavirenz. For 
participants who later developed clinical or laboratory 
evidence of ART treatment-failure or toxic effects, available 
second-line agents were didanosine, zidovudine, tenofovir 
and emtricitabine.
3. Results
  A total of 342 adult HIV infected patients were recruited 
during the study period. This comprised of 90 males (26.3%) 
and 252 females (73.7%) with a male-to-female ratio of 
1:2.8. The overall mean age of the patients was (40依10) 
years with a median of 39 years. The baseline demographic 
characteristics of the subjects are captured in Table 1. 
Majority of the patients (39.2%) were in the age bracket 31-
40 years with a female preponderance. A total of 214 (62.6%) 
participants were asymptomatic, presenting in stage 1 and 
2, while 128 (37.4%) symptomatic patients presented in 
advanced stage disease (3 and 4). Of the 342 participants, 
134 (39.2%) had a CD4+ cell count less than 200 cells/毺L, 
42 (12.3%) were in 201-350 cells/毺L, 54 (15.8%) in 351-500 
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cells/毺L, and 112 (32.7%) were >500 cells/毺L.
Table 1
Baseline information on study population.
Age (years) Male (%) Female (%) Total (%)
<20  2 (0.6)   4 (1.2)    6 (1.8)
21-30  6 (1.8)   43 (12.6)    49 (14.3)
31-40 28 (8.2) 106 (31.0)   134 (39.2)
41-50   36 (10.5)   53 (15.5)    89 (26.0)
51-60 14 (4.1)   45 (13.2)    59 (17.3)
>60   4 (1.2)    1 (0.3)    5 (1.5)
  Table 2 revealed that 254 subjects (74.3%) were found to 
have malaria parasitemia. This gives a negative smear for 
Plasmodium falciparum in 25.7% of the study patients. A 
total of 214 (62.6) with HIV progression were symptomatic 
(stage 3-4), out of which 147 (43.0%) had parasitemia. The 
odds of having malaria parasitemia increased with advancing 
clinical stage of HIV infection and this was statistically 
significant (P=0.002, OR=2.32). The 254 co-infected HIV and 
malaria infections had a mean age of 39.8依9.7. There was no 
statistical significance when gender was compared with the 
malaria status (P >0.05). 
  There was a significant association between CD4+ cell 
count ≤200 cells/毺L and having significant parasitemia 
(P < 0.0001) as shown in Table 3. About half (50.8%) of 
co-infected patients had CD4+ cell count ≤200 cells/毺L 
with majority (44.9%) of this population having significant 
parasitemia. The odds of significant parasitemia increased 
with falling CD4+ cell count. Individuals with CD4+ cell 
count≤200 cells/毺L had higher risk of malaria parasitemia 
compared to those with CD4+ cell count >200 cells/毺L. 
  The selected blood findings obtained from the co-
infected patients are shown in table 4. The overall mean 
parasite count was (2.37依0.20)伊109/L with a median of 
1.3伊109/L. Of the 254 co-infected patients, 134 (52.8%) 
had high parasitemia (>1.25伊109/L) with a mean parasite 
count of (3.78依0.37)伊109/L. Sixty patients were found to be 
hyperparasitemic (>2.5伊109/L). The prevalence of anaemia 
(Hb≤10g/dL) in HIV and malaria co-infected patients was 
33.1% with a mean value of (9.15依0.11) g/dL while 21.7% 
were thrombocytopenic (≤150伊109/L) with a mean of (107.5依
4.4)伊109/L and a range of (33-150)伊109/L. 
4. Discussion
  Mounting evidence has revealed pathological interactions 
between HIV and malaria in dually infected patients, but 
the implications of the interplay have remained unclear. 
Given the extensive overlap in the geographic distribution 
of malaria and HIV infections, even modest interactions 
between them would have enormous public health 
importance. Recent evidence clearly supports presence 
of the significant impact of each infection on the other 
and by extension on the individuals[18,19]. Majority of the 
HIV subjects were within the age bracket 31-40 years, 
representing the economic age bracket and this has serious 
socio-economic impact on the nation.
  The CD4+ T cells are crucial in immune responses against 
HIV virus and malaria parasite infection. Plasmodium 
falciparum has been shown to stimulate HIV replication 
through the production of cytokines (inteleukin 6 and tumor 
necrosis factor alpha) by activated lymphocytes[11,12]. Our 
study revealed that 39.2% of the subjects had low CD4 cell 
Table 2
Clinical stage and gender prevalence of Plasmodium malaria infection in study population.
Characteristic Malaria infected (%) Malaria uninfected (%)        Total (%)
Clinical stage Asymptomatic (1-2) 107 (31.3)  21 (6.1)         128 (37.4)
Symptomatic (3-4) 147 (43.0)    67 (19.6)         214 (62.6)
Gender Male   72 (21.1) 18 (5.3)            90 (26.3)
Female 182 (53.2)    70 (20.5)           252 (73.7)
Table 3
Relationship between CD4 cell count and significant parasitemia among co-infected patients (n = 254).
CD4+ cell  count(/毺L)     Significant parasitemia (≥1.25伊10
9/L) Non significant parasitemia (<1.25伊109/L) Total
≤200   114 (44.9%)   15 (5.9%) 29 (50.8%)
>200   20 (7.8%)    105 (41.3%) 125 (49.2%)
Table 4
Selected laboratory data of co-infected malaria and HIV patients during the study period (n =254).
Lab data Frequency (%)  Mean Median Range
Parasite density (伊109/L) Low (0.1-0.6)   46 (18.1)      0.37依0.03      0.4 0.1-0.6
Medium (0.7-1.2)   74 (29.1)      0.77依0.03      0.8 0.7-1.1
High (> 1.25) 134 (52.8)      3.78依0.37     1.3   1.2-18.9
Haemoglobin (g/dL) ≤10   84 (33.1)      9.15依0.10     9.2   6.6-10.0
>10 170 (66.9)    12.30依0.10    12.1 10.1-19.6
Platelet (1.25伊109/L) ≤150   55 (21.7)  107.50依4.40   116.0    33.0-15030
>150 199 (78.3)  250.00依5.10    229.0 151.0-517.0
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count of 200 cells/毺L and below. This is not surprising as 
the CD4+ T cells are targeted for destruction by HIV virus 
in addition to the malaria parasite. Former reports mention 
that HIV-1 patients with a CD4 count 200 cells/毺L have a 
higher risk of parasitemia or clinical malaria compared to 
those with a higher CD4 count[8,20]. Cellular mechanisms, 
including CD4+ cells, responsible for protection against 
malaria, built up over a period of time as a result of repeated 
malaria attacks are destroyed in HIV infected individuals, 
thus leading to increased parasitemia and clinical malaria. 
  Our study revealed that majority (74.3%) of HIV subjects 
had malaria infection as opposed to only 25.7% who had no 
malaria infection and this was statistically significant. Being 
in a stable transmission area, the HIV positive individuals 
are more likely to be exposed to malaria hence, the increase 
prevalence of parasitemia cases seen in the study regardless 
of whether symptoms were present or not. This collaborates 
with other studies where there was an increase incidence, 
prevalence and severity of malaria in HIV infected 
individuals[18,21,22]. This is because HIV infection is known 
to lead to a progressive cellular immunosuppression with a 
resultant impairment in immune response to malaria. 
  Recent investigations suggest that HIV positive individuals 
with reduced CD4 cell count may be more likely at risk to 
present with malarial parasitemia[23]. In our study, majority 
of the subjects with low CD4+ cell count of 200 cells/毺L was 
significantly associated with high parasitemia. A similar 
study showed that individuals with CD4+cell counts less 
than 200 cells/毺L had six times the odds of having malaria 
compared with those with CD4+ cell counts of at least 500 
cells/毺L[8]. The odds of having clinical malaria at a routine 
visit were reported to increase with advancing clinical stage 
of HIV-1 infection. This increase was most evident for visits 
of individuals in WHO stage 4, at which the odds were nine 
times those in stage 1. 
  Based on WHO clinical stages, there were an increasing 
number of patients with malaria infection with advancing 
HIV disease, although the setback here was the difficulty 
in separating stages 1 and 2. Majority of the co-infected 
patients (50.8%) had significant high parasitemia with 
60 patients having hyperparasitemic counts (>2.5伊109/L 
parasite count); though we did not record any form of death 
during the study period. This may be because those with a 
high degree of acquired immunity may be able to sustain 
sufficient antitoxic immunity to avoid severe disease despite 
HIV-associated immunosuppression[24]. Hospital-based 
studies in Zambia and Burundi found increased malaria 
case fatality ratios in patients with HIV compared with 
HIV-seronegative individuals, but the small sample sizes 
did not allow firm conclusions to be drawn[25,26]. A study in 
rural Kwazulu-Natal, an area of unstable malaria reported 
that HIV-infected children were more likely to experience 
severe disease, coma and death[27]. However, the high 
parasite densities found in our study is in contrast to the low 
parasite densities reported in an urban cohort population in 
Uganda[28]. Investigators have speculated that because HIV 
infection increases parasitaemia and reduces the response 
to therapy, it will increase the reservoir of infection in the 
human population and hence increase transmission[21,29]. 
In all, they did not take into account the wide variation 
in immunosuppression found at different stages of HIV-1 
infection. 
  Haematological abnormalities are considered a hallmark of 
malaria and reported to be most pronounced in plasmodium 
falciparum infection[30]. Anaemia is said to be a common 
feature of malaria and HIV independently. This study 
however, could not establish this assertion as majority 
(66.9%) of the coinfected patients had haemoglobin level 
> 10 g/dL as against 52.8% reported among HIV-positive 
population and characteristics of anaemia of chronic disease 
in a Nigerian study[31,32]. The mean value of (9.15依0.11) g/
dL recorded in our study is similar to 9.17依1.67 recorded for 
parasitized HIV infected in another part of the country[33]. 
The pathogenesis of anaemia in plasmodial parasitized 
patients is complex and multifactorial. They are thought to 
result from haemolysis of parasitized red cells, exacerbated 
removal of parasitized red cells, depressed and ineffective 
erythropoiesis[34]. Similarly, thrombocytopenia has been 
reported as a classical feature of malaria and low platelet 
count is usually seen in 72% of patients with uncomplicated 
malaria[35]. The platelet count of most individuals in this 
study was within normal range. Again, this could be because 
all the co infected individuals were already on the HAART 
therapy. In-vitro studies have shown that some components 
of the human immune response to Plasmodium falciparum 
are modified by HIV-1 but that others are unaffected[10,36].
  In conclusion, our findings indicate that there is an 
increased prevalence of malaria parasitemia among HIV 
infected individuals in an endemic region. With the 
HAART therapy already instituted in Nigeria, the next step 
presumably is effective prevention and interventions in form 
of regular malaria prophylaxis as this is known to reduce 
the risk of malaria in HIV infected patients especially in sub 
Saharan areas where coinfection is common. 
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